2024-04-29-上交所科创板-2023_Annual_Environmental,_Social_and_Governance（ESG）_Report_45页_6mb

2023 Annual Environmental, Social and Governance Report: Shanghai Aohua Endoscopy Co.,Ltd.

Executive Summary

• Shanghai Aohua Endoscopy Co., Ltd. (hereinafter referred to as "Aohua" or "the Company") released the 2023 Annual Environmental, Social, and Governance (ESG) Report. The report details the Company's commitment and performance in achieving sustainable development, integrating Environmental protection, Social responsibility, and robust Governance practices across its operations.
• Key Areas Discussed:
  1. Products Innovation and Market Impact: Aohua successfully launched innovative product lines (e.g., AQ-200 Elite, AQ-300 Ultra HD, dual-focus endoscopes) contributing to significant revenue growth and enhancing its market position, setting a standard in the domestic medical equipment sector.
  2. ESG Strategy: The Company embeds ESG principles into its corporate governance structure, ensuring transparency, compliance, and stakeholder engagement.
  3. Social Responsibility: Aohua focuses extensively on patient-centricity through early cancer screening promotion, charitable donation initiatives (e.g., donating ¥3.4 million worth of equipment to support early cancer detection in rural areas), rural support programs, and collaborations to enhance diagnostic and therapeutic capabilities.
  4. Global Reach and Quality Management: The Company continuously expands its global presence and emphasizes compliance with international standards (like ISO 13485, EU MDR) for product quality and safety.
  5. Governance and Investor Relations: The Company maintains a transparent structure under the Board of Directors' oversight, ensuring ethical conduct and robust decision-making.

Detailed Content Summary

I. Environmental, Social, and Governance (ESG)

• Materiality Assessment:

  • Environmental: Addressing Green Operations (Energy Consumption Intensity, reduction).
  • Social: Focusing on Employee Health and Safety (overseeing absence), Protecting Employee Rights (discrimination-free workplace), early Cancer Prevention and Rural Support.
  • Governance: Compliance with global regulations (MDR EU, KGMP KOR) and Supplier Management Audits.

• Environmental Management:

  • The Company obtained ISO 14001 Certification (Environmental Management System).
  • Sustains low environmental impact through efficient operations and pollution reduction initiatives (e.g., adjustable focus technology enhancing diagnostic precision for surgeons).

• Social Responsibility:

  • Early Cancer Prevention: Promote the use of CBI spectral staining for better lesion detection; organized workshops to enhance doctors' skills and screen at-risk individuals.
  • Rural Support: Collaborated on medical exchange programs, improving access to advanced endoscopy techniques in underdeveloped areas.
  • Charitable Donation: Transferred ¥3.4 million in medical equipment to support early cancer screening.

• Governance:

  • Board Oversight: Strong Board (9 directors, 4 independent), including Audit, Compensation, and Nomination Committees ensuring strategic governance.
  • Stakeholder Engagement: Regular feedback mechanisms, addressing investor concerns aligned with regulatory compliance and shareholder returns.
  • Intellectual Property Protection: Maintained strong IPR portfolio (349 IPs granted, 164 pending), securing patents and design rights.

II. Innovation and Enterprise

• Innovation Focus:

  • Continuous enhancement in product design: High-definition endoscopes, dual-focus mesh adapters (4K UHD imaging), and ultra-slim devices (1.8mm diameter).
  • Medical Design Innovation: iF Design Award for products and international recognition (e.g., Shanghai Design 100+).
  • Medical Technology Development: Participated in 2023 iF Design Award and Red Dot design awards for advanced endoscopic systems.

• Research, Development Mission, and Talent:

  • R&D investment grew to ¥147 million (44.49% YoY), with 233 employees in R&D (21.34% of workforce).
  • Collaborations with medicine and engineering institutions to improve product performance and accuracy.

III. Key Performance for 2023

• Financial Highlights:
  • Revenue reached ¥678.08 million, achieving a 116.7% YoY growth.
  • Net profit attributable to shareholders: ¥57.85 million (90.44% YoY).

IV. Quality Management

• Product Quality:
  • High-quality product performance (e.g., 100% flawless execution) backed by ISO 13485, ISO 9001:2015.
  • Adherence to rigorous quality assurance protocols throughout development and production.

This analysis provides a concise summary of the key points within the Shanghai Aohua Endoscopy 2023 ESG report, focusing on structure, content themes, and adherence to ESG criteria.